BioSphere Medical, Inc. (NASDAQ: BSMD), the medical device company that pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a procedure called embolization, announced today that Martin Joyce, Executive Vice President and Chief Financial Officer, is scheduled to present at the Roth 2007 New York Conference at 9:00 a.m. ET on Thursday, September 6, 2007. The event is taking place at the Westin Times Square in New York City.

The presentation will be available on the ?Investors? section of BioSphere Medical's website at www.biospheremed.com. To listen to the live event, go to the website at least 15 minutes early to register, download and install any necessary audio software. A replay of the webcast will be available at the Company's website for 90 days following the presentation.

About BioSphere Medical, Inc.

BioSphere Medical, Inc., a medical device company based in Rockland, Massachusetts, seeks to pioneer and commercialize minimally invasive diagnostic and therapeutic applications based on proprietary bioengineered microsphere technology. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with unique beneficial properties for a variety of medical applications. BioSphere's principal focus is the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE. The Company's products continue to gain acceptance in this rapidly emerging procedure as well as in a number of other new and established medical treatments.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For a discussion of important risks and uncertainties which could cause actual results to differ from those contained in such forward-looking statements, see "Risk Factors" in BioSphere's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, as filed by the Company with the Securities and Exchange Commission, and described in other filings made by the Company from time to time with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date of this press release and the Company disclaims any obligation to update these forward-looking statements as a result of changed events, circumstances or otherwise.

BioSphere Medical, Inc.
Martin Joyce, 781-681-7925
Executive Vice President and
Chief Financial Officer
or
Investor Relations:
The Equity Group Inc.
Devin Sullivan, 212-836-9608
Senior Vice President